NCT05110781View on ClinicalTrials.gov

Atezolizumab Before Surgery for the Treatment of Regionally Metastatic Head and Neck Squamous Cell Cancer With an Unknown or Historic Primary Site

PHASE2TerminatedINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

December 7, 2021

Primary Completion Date

May 2, 2022

Study Completion Date

April 18, 2023

Conditions
Locally Advanced Cutaneous Squamous Cell Carcinoma of the Head and NeckResectable Cutaneous Squamous Cell Carcinoma of the Head and NeckStage III Cutaneous Squamous Cell Carcinoma of the Head and Neck AJCC v8
Interventions
BIOLOGICAL

Atezolizumab

Given IV

RADIATION

Radiation Therapy

Undergo radiation therapy

PROCEDURE

Therapeutic Conventional Surgery

Undergo surgery

Trial Locations (1)

95817

University of California Davis Comprehensive Cancer Center, Sacramento

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Genentech, Inc.

INDUSTRY

lead

Arnaud Bewley, MD

OTHER